Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-19
2006-09-19
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S576000, C514S577000, C514S717000, C514S730000, C514S736000, C568S579000, C568S583000, C568S585000, C568S588000, C568S626000, C568S630000, C568S635000
Reexamination Certificate
active
07109164
ABSTRACT:
New thyroid receptor ligands are provided which have the general formulain which:X is —O—, —S—, —CH2—, —CO—, or —NH—;Y is —(CH2)n— where n is an integer from 1 to 5, or cis- or trans-ethylene;R1is halogen, trifluoromethyl, or alkyl of 1 to 6 carbons or cycloalkyl of 3 to 7 carbons;R2and R3are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 6 carbons, at least one of R2and R3being other than hydrogen;R4is hydrogen or lower alkyl;R5is hydrogen or lower alkyl;R6is carboxylic acid, or esters or prodrugs;R7is hydrogen or an alkanoyl or an aroyl.In addition, a method is provided for preventing, inhibiting or treating a disease associated with metabolism dysfunction or which is dependent upon the expression of a T3regulated gene, wherein a compound as described above is administered in a therapeutically effective amount. Examples of such diseases associated with metabolism dysfunction or are dependent upon the expression of a T3regulated gene include obesity, hypercholesterolemia, atherosclerosis, cardiac arrhythmias, depression, osteoporosis, hypothyroidism, goiter, thyroid cancer as well as glaucoma, congestive heart failure and skin disorders.
REFERENCES:
patent: 5401772 (1995-03-01), Yokoyama et al.
patent: 6194454 (2001-02-01), Dow
patent: 2001/0051657 (2001-12-01), Chiang et al.
patent: 1078582 (1960-03-01), None
patent: 0580550 (1997-10-01), None
patent: 1088819 (2001-04-01), None
patent: WO 99 00353 (1999-01-01), None
patent: WO 00/51971 (2000-08-01), None
patent: WO 00/58279 (2000-10-01), None
patent: WO 01/85670 (2001-11-01), None
Dermer, Gerald ‘Another Anniversary for the War on Cancer’ Bio/technology, vol. 12, Mar. 1994, p. 320.
Gura, Trisha ‘Systems of Identifying New Drugs are Often Faulty’ Science, vol. 278, Nov. 1997, pp. 1041-1042.
Golden, Fredrick, ‘Of Mice and Men Don't Blame the Rodents.’ Time, May 1997, pp. 44.
The Merck Manual (ed. R. Berkow), ‘Scaling Papular Disease’, Ch. 239, pp. 2435-2439, Sixth ed., 1992.
File medline on STN. AN No. 90150816. Zugerman, C. ‘Chloracne. Clinical Manifestatoin and Etiology’, Dermat. Clin. Jan. 1990, vol. 8, No. 1, pp. 209-213. Abstract only. Abstract date 1990.
The Merck Manual, ‘Keloid’ [online retrived on Dec. 13, 2003]. Retrived from the internet <http://www.merck.com/mrkshared/mmanual/section10/chapter125/125k.jsp>.
“Computerized Drug Design: Still Promising, Not Yet Here”, Science, vol. 256, pp. 441, Apr. 24, 1992.
Yokoyama, N., J. Med. Chem., vol. 38, pp. 695-707, 1995.
Friends Todd J.
Ryono Denis E.
Zhang Minsheng
Bristol--Myers Squibb Company
Duncan, Jr. Sammy G.
Gupta Anish
LandOfFree
Aniline-derived ligands for the thyroid receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aniline-derived ligands for the thyroid receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aniline-derived ligands for the thyroid receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3551796